University of Patras
Λιποσώματα που ενσωματώνουν αρσονολιπίδια: επίδραση της λιπιδικής σύστασης ή / και επικάλυψης της λιποσωματικής μεμβράνης με πολυαιθυλενογλυκόλη στη σταθερότητά τους, στην αλληλεπίδρασή τους με κύτταρα (in vitro) και στην βιοκατανομή τους
Abstract
dc:descriptionIn this study we investigated the behavior of arsonolipid containing liposomes, in respect with their lipid composition and its effect on their stability, their interactions with normal and cancer cells and their biodistribution. Sonicated arsonoliposomes were prepared using arsonolipid with palmitic acid acyl chain (Ars), mixed with cholesterol (Chol) and phosphatidylcholine (PC-based arsonoliposomes) or 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC-based arsonoliposomes), with PC/Ars/Chol and DSPC/Ars/Chol 12:8:10 molar ratio. Arsonoliposomes with PC/Ars/Chol and DSPC/Ars/Chol 17:3:10 molar ratio was also studied. PEG2000-lipid (1,2-distearoyl-sn-glycero-3-phosphoethanolamine conjugated to polyethylenoglycol 2000) containing vesicles (PEGylated arsonoliposomes, PC-based and DSPC-based) were also prepared. Sonicated liposomes were also prepared using phosphatidylcholine or 1,2-distearoyl-sn-glycero-3-phosphocholine, both mixed with cholesterol, PC/Chol and DSPC/Chol 2:1 molar ratio. The cytotoxicity of these arsonoliposomes towards different cancer cells (human promyelocytic leukemia (NB4), prostatic cancer (PC3), human breast adenocarcinoma (MDA-MB-468), human T-lymphocyte (MT-4) and also towards HUVEC (human umbilical vein endothelial cells) was evaluated by calculating the arsonoliposome-induced growth inhibition of the cells by the MTT assay. IC50 values were interpolated from cell number/arsonolipid concentration curves. The results reveal that all types of arsonoliposomes evaluated significantly inhibit the growth of most of the cancer cells studied (PC3, NB4 and MT-4) with the exception of the MDA-MB-468 breast cancer cells, which were minimally affected by arsonoliposomes in some cases even less than HUVEC. Nevertheless, for the same cell type the differences between the different types of arsonoliposomes were significant but never proportional to their stability, indicating that high rigidity of the arsonoliposome membrane is not a problem for their anticancer activity. Thereby it is concluded that arsonoliposome composition should be adjusted accordingly depending on their in vivo kinetics and the desired biodistribution. The interaction of liposomes with NB4 and MDA-MB-468 cells (cells with minimum and maximum viability after interaction with the arsonoliposomes accordingly) was monitored by a fluorescence method, which allows for the simultaneous monitoring of endocytosis, binding and leakage. Pyranine (1-hydroxypyrene-3,6,8-trisulfonic acid, HPTS), a highly fluorescent, water-soluble, pH sensitive dye, was encapsulated at high concentration into the lumen of liposomes. HPTS exhibits two major fluorescence excitation maxima (403 and 450 nm), which have a complementary pH dependence. The intensity of fluorescence of HPTS at 413 nm (the isosbestic point of HPTS) is pH-independent, while the intensity of fluorescence at 454 nm is pH-dependent. NB4 and MDA-MB-468 cells were incubated at 37 oC with HPTS-encapsulating liposomes for different time periods and the intracellular fate of liposomes was monitored by measuring the fluorescence, at excitation wavelengths of 413 nm and 454 nm and an emission wavelength of 512 nm. The ratio of the fluorescence intensities (Ι454/Ι413) was calculated and evaluated, since it serves as an indicator of liposomes intracellular fate. In order to gain quantitative proof concerning the localization of cell-associated liposomal fluorescence in endosomes or lysosomes of NB4 and MDA-MB-468 cells, after incubation with HPTS-encapsulating liposomes, the cells were incubated with NH4Cl. This results in an increase of pH in the acidic cellular compartments, which would induce an increase in HPTS fluorescence at 454 nm, if the dye is localized in cell endosomes (i.e. lysosomes). This effect can be reversed by removal of NH4Cl. The ratio Ι454/Ι413 was calculated, before and after NH4Cl incubation, as well as after its removal. The % uptake of liposomal contents by cells and their subsequent exposure to acidified endosomes or secondary lysosomes was also monitored. The intensity at 413 nm serves as a measure of total number of liposomes associated with cells, regardless of their location along the endocytotic pathway. The concentration of dye associated with cells was determined by measuring fluorescence at 413 nm (pH independent point) and comparing the results to a standard curve, after incubation of NB4 and MDA-MB-468 cells at 37 oC with HPTS-encapsulating liposomes for different time periods. Fluorescence microscopy studies were performed to visualize the uptake of HPTS-encapsulating arsonoliposomes in NB4 and MDA-MB-468 cells. The intra- and extracellular distribution of Rho-PE-arsonoliposomes (arsonoliposomes with 0,2% rhodamine conjugated with phosphatidyl-ethanolamine in their lipid composition), was observed after incubation with cells at 37 oC for different time periods, by fluorescence microscopy, using appropriate excitation and barrier filters. Furthermore, in another set of experiments, pretreatment of cells with endocytosis inhibitors was performed. Chloropromazine (clathrin mediated endocytosis inhibitor, CPZ) and methyl-β-cyclodextrin (caveolae mediated endocytosis inhibitor, ΜeβCD) were preincubated with cells, HPTS- encapsulating liposomes were added and the Ι454/Ι413 ratio and the % uptake of liposomal contents by cells were measured for different time periods., in order to clarify in which cases the endocytosis is clathrin- or caveolae-dependent. The interaction of liposomes with cells was monitored at 4 oC as well, in order to study the time-course of the binding of liposomes to cells and clarify whether the mechanism of the association of liposomes with cells is energy dependent. NB4 and MDA-MB-468 cells were incubated at 4 oC with HPTS-encapsulating liposomes for different time periods in two different concentrations and the estimation of the intracellular fate and amount of bound liposomes on the cells was once again based on of Ι454/Ι413 ratio and uptake measurements. The mechanism of the association of the liposomes seems to be similar for all arsonoliposomes in the case of MDA-MB-468 cells. The results reveal that arsonoliposomes are uptaken by a receptor-mediated mechanism, probably clathrin- or/and caveolae-mediated. In comparison with the results of the viability studies, the fact that arsonoliposome did not induce growth inhibition of the MDA-MB-468 cells may correlate to their lysosomal degradation resulting from the clathrin-mediated endocytosis. Moreover, the fact that no arsenic was detected by Graphite Furnace Atomic Absorbance Spectrometry in the cells after incubation under the same conditions, except for the more rigid DSPC arsonoliposomes (PEGylated or not), comes in agreement with this previous hypothesis. In the case of NB4 cells, the mechanism of the association and the extent of receptor-mediated endocytosis role may affect the induced growth inhibition. More cytotoxic PEGylated PC-based arsonoliposomes are not endocytosed through receptors at all, while PEGylated DSPC-based seem to be endocytosed through clathrin- or/and caveolae-mediated mechanism. The fact though that no arsenic was detected, after both cancer cell lines were incubated with all arsonoliposomes studied under identical conditions, needs further investigation, given that whole liposomes internalization is taking place and that control liposomes (with no arsenic in their lipid composition) have been found not to be toxic against cancer cells. In order to study the biodistribution of arsonoliposomes, DSPC-based and PEGylated DSPC-based arsonoliposomes, were administered by intraperitoneal (i.p.) injection in balb-c mice and the distribution of arsenic in the organs after 1, 2, 5, 12 and 24h post-injection was measured by atomic absorption spectroscopy. Results demonstrate that a high portion of the dose administered is rapidly excreted, since 1h post-injection only about 30–40% of the dose was detected cumulatively in animal tissues. After this, the whole body elimination of arsenic was a slow process with a half-life of 27.6 h for PEGylated DSPC-based arsonoliposomes, and 83 h for the DSPC-based ones. For both arsonoliposomes, arsenic distribution was greater in intestines, followed by liver, carcass + skin stomach, spleen, kidney, lung and heart. Different arsenic kinetics in blood between the two liposome types was observed. Compared to the results obtained previously with PC-based arsonoliposomes, both the DSPC-based and PEGylated-arsonoliposomes have better bioavailability. This proves that arsonoliposome lipid composition (and consequently their integrity) influences their pharmacokinetic profile. Thus, the proper arsonoliposome composition should be used according to the intended application. The same set of in vivo studies were also performed with DSPC-based and PC-based arsonoliposomes intravenous (i.v.) injection. In all cases PEG-lipid (1,2-distearoyl-sn-glycero-3-phosphoethanolamine conjugated to polyethylenoglycol 2000) was also added in the lipid membrane of the arsonoliposomes (PEGylated-arsonoliposomes) at 8 mol %. The liposomes were injected intravenously in balb-c mice. For all arsonoliposome types, the biodistribution of arsenic in mice organs was measured by atomic absorption spectroscopy, at 1, 3 and 24 h post-injection. DSPC-based arsonoliposomes give higher arsenic levels in most tissues (compared to PC-based ones) and are also affected to a higher extent by surface PEGylation. PEGylated DSPC arsonoliposomes behave similarly to PEGylated conventional liposomes that bear anionic charge. By comparison with the previous biodistribution values obtained after intraperitoneal administration of most of the vesicle types studied herein, it is concluded that the administration route has a significant effect on arsonoliposome kinetics, in some ways similar to that observed for conventional liposomes. Interestingly, after i.v. injection of all the arsonoliposome types tested, arsenic was found in detectable amounts in the animal brains, indicating that perhaps arsonoliposomes (intact or not) can pass the brain barrier to a certain extent, when high vesicle concentrations are present in the bloodstream.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Zagana, Paraskevi
- Ζαγανά, Παρασκευή
Subjects
dc:subject × 22- Αρσενικό
- Λιποσώματα
- Αρσονολιπίδια
- Αρσονολιποσώματα
- Λιπιδική σύσταση
- Επικαλύψη με πολυαιθυλενογλυκόλη
- Σταθερότητα λιποσωμάτων
- Βιοκατανομή
- Αντικαρκινική δράση
- Arsenic
- Liposomes
- Arsonolipids
- Arsonoliposomes
- Lipidic composition
- PEG coating
- Liposome stability
- Bioavailability
- Anticancer activity
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/34155